7 results about "Coated capsule" patented technology

The present invention relates to an enteric-coated capsule for the release of a sedative and / or analgesic and / or relaxing active ingredient, comprising a capsule base body having a capsule wall that is closed on all sides and forming a cavity within which the active ingredient is arranged.

The application belongs to the technical field of medicine, and particularly relates to a self-releasing microcapsule for intestinal sampling and application thereof. The self-releasing microcapsule comprises a capsule cavity, a capsule shell, a sealing member and a coating. The capsule shell is provided with a sampling hole, the capsule cavity is internally provided with sampling hydrogel for absorbing sample fluid, the sealing member is arranged in the capsule cavity between the sampling hydrogel and the sampling hole, wherein the expansion of the sampling hydrogel in the capsule cavity presses the sealing member to engage with the sampling hole to seal the capsule cavity, and the coating is arranged on the surface of the capsule shell. The coating comprises the following coating materials in parts by weight: 15-20 parts of hydroxypropyl methyl cellulose phthalate, 25-30 parts of Eudragit L100, 8-12 parts of algal extract, 1-3 parts of polyethylene glycol and 1-2 parts of talc. The self-releasing microcapsule can be used for precise sampling of the colon.

The invention provides an omeprazole enteric capsule and a preparation method thereof, and belongs to the technical field of medicines. The omeprazole enteric-coated capsule is prepared by taking an omeprazole derivative as an active component and embedding the omeprazole derivative through a sustained-release enteric-coated material. According to the omeprazole enteric capsule prepared by the invention, by adjusting the molecular structure of omeprazole, the water solubility and the bioavailability of omeprazole are improved, the half-life period is prolonged, and by embedding the sustained-release enteric material, the targeted slow release of intestinal tracts is realized, so that the drug effect time is prolonged, the problem of repeated medication is avoided, the compliance of patients is improved, and the bioavailability of the omeprazole enteric capsule is improved. Wide application prospects are realized.

This invention relates to an anti-brittle enteric-coated gelatin hollow capsule shell, belonging to the field of hollow capsule production technology. Addressing the problems of low mechanical strength, easy breakage during storage and transportation, and increased brittleness due to high coating ratios in existing enteric-coated capsule shells, this invention significantly improves the anti-brittleness of the capsule shell while ensuring enteric properties. It utilizes a synergistic compounding of gelatin, humectants, surfactants, plasticizers, modifiers, disintegrants, opacifiers, and enteric coating materials, combined with a "step-by-step coating and online precise temperature-controlled drying" process. The product meets the pharmacopoeia's brittleness requirements for a 20g weight and passes a 100g weight strengthening test. It exhibits structural stability, low breakage rate, and is suitable for high-load packaging transportation and long-term storage, making it widely applicable to various enteric-coated drug formulations.

The invention provides a budesonide enteric capsule, which is characterized in that resveratrol is used as a pellet core, budesonide, zein, hydroxypropyl methylcellulose acetate succinate, polyvinylpyrrolidone, acetyl triethyl citrate and tween-80 are used for preparing a budesonide sustained-release pellet, and the budesonide enteric capsule is prepared from the budesonide, the zein, the hydroxypropyl methylcellulose acetate succinate, the polyvinylpyrrolidone, the acetyl triethyl citrate and the tween-80. Cellulose acetate phthalate and zinc pectin are adopted to prepare the budesonide enteric-coated sustained-release pellet, and the budesonide enteric-coated capsule prepared through filling has the enteric-coated characteristic, and the effect is better than that of single use of cellulose acetate phthalate or zinc pectin as an enteric-coated material; and the budesonide enteric capsule prepared by taking resveratrol as the pellet core has better ulcerative colitis treatment effect than the budesonide enteric capsule prepared by taking cane sugar as the pellet core.

The present invention relates to a modified-release solid oral pharmaceutical composition, which is in the form of an enteric-coated capsule, wherein said capsule comprises cannabidiol (CBD), tetrahydrocannabinol (THC) and an emulsifier, and wherein the capsule optionally further comprises one or more cannabis terpenes. The solid oral pharmaceutical composition provided herein has a particularly advantageous modified release profile as well as an improved oral bioavailability as compared to conventional formulations of CBD and THC.

The invention relates to the technical field of pharmaceutical preparations, and discloses an aceclofenac enteric capsule and application thereof in rheumatoid arthritis, and the aceclofenac enteric capsule composition comprises the following components in parts by weight: aceclofenac, choline-aspartate ionic liquid, sodium alginate, low methoxyl pectin and micronized calcium carbonate. The invention aims to solve the technical problems that aceclofenac is poor in solubility and a conventional enteric-coated preparation has a burst release effect. According to the composition, a pH-sensitive in-situ gel drug delivery system is constructed; when the content of the composition is in a gastric acid environment, micronized calcium carbonate is activated and calcium ions are released in situ; and after entering the neutral environment of the intestinal tract, the calcium ions are crosslinked with the sodium alginate and the low-methoxyl pectin, so that the liquid content is quickly converted into semi-solid gel with biological adhesiveness. The system realizes the positioning retention and long-acting slow release of the medicine in the intestinal tract, effectively avoids the violent fluctuation of the blood concentration, and is expected to improve the bioavailability of the medicine.